TF and prostate neoplasm: The PAMAM-PEG-Angiopep/pORF-TRAILNPs could penetrate the blood–brain barrier (BBB) and target glial cellsbased on Angiopep-2-mediated delivery, with hight transfection efficiency.Another strategy has been reported in which transferrin (Tf) was conjugatedto a generation 3 diaminobutyric polypropylenimine (DAB) dendrimer; thisdelivery system harbors plasmids encoding for TNF-α, TRAIL, or IL-12 andleads to therapeutic effects on prostate tumors following intravenousadministration [63].